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Abstract
Importance—Previous studies have reported that histopathologically amelanotic melanoma is 
associated with poorer survival than pigmented melanoma; however, small numbers of amelanotic 
melanomas, selected populations, lack of centralized pathology review, or no adjustment for stage 
limit interpretation or generalization of results from prior studies.
Objective—To compare melanoma-specific survival between patients with histopathologically 
amelanotic and those with pigmented melanoma in a large international population-based study.
Design—Survival analysis with median follow-up of 7.6 years.
Setting—The Genes, Environment, and Melanoma study enrolled incident cases of melanoma 
diagnosed in 1998-2003 from international population-based cancer registries.
Participants—A total of 2,995 patients with 3,486 invasive primary melanomas centrally scored 
for histologic pigmentation.
Main Outcomes and Measurements—Clinicopathologic predictors and melanoma-specific 
survival of histologically amelanotic and pigmented melanoma were compared using generalized 
estimating equations and Cox regression models, respectively.
Results—Eight percent of melanomas (275 of 3,467) were histopathologically amelanotic. 
Female sex, nodular and unclassified or other histologic subtypes, increased Breslow thickness, 
presence of mitoses, severe solar elastosis, and lack of a co-existing nevus were independently 
associated with amelanotic melanoma (each P < .05). Amelanotic melanoma was generally of a 
higher American Joint Committee on Cancer (AJCC) tumor stage at diagnosis (P for trend <.001) 
than pigmented melanoma. Hazard of death from melanoma was higher for amelanotic than 
pigmented melanoma [hazard ratio (HR), 2.0; 95% confidence interval (CI), 1.4-3.0; P< .001], 
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adjusted for age, sex anatomic site, and study design variables; but survival did not differ once 
AJCC tumor stage was also taken into account, (HR, 0.8; 95% CI, 0.5-1.2; P = .36).
Conclusions and Relevance—At the population level, survival after diagnosis of amelanotic 
melanoma is poorer than after pigmented melanoma because of its more advanced stage at 
diagnosis. It is probable that amelanotic melanomas present at more advanced tumor stages 
because they are difficult to diagnose. The association of amelanotic melanoma with presence of 
mitoses independently of Breslow thickness and other clinicopathologic characteristics suggests 
that amelanotic melanomas might also grow faster than pigmented melanomas. New strategies for 
early diagnosis and investigation of the biology of amelanotic melanoma are warranted.
Keywords
amelanotic melanoma; epidemiology; pathology; skin cancer; pigmentation; neoplasm staging
Introduction
The American Cancer Society has estimated that 76,100 new invasive melanomas will be 
diagnosed and 9,710 people will die from melanoma in 2014 in the United States.1 Despite 
newly available targeted and immunomodulatory agents,2-5 systemic therapies rarely lead to 
cures. Thus, early detection of primary melanomas followed by surgical excision remains 
critical for good outcomes. While recognition of all melanomas can be difficult, visual lack 
of brown or black color in amelanotic melanoma at the time of clinical diagnosis removes a 
defining characteristic for melanoma identification. Several studies indicate that amelanotic 
melanoma is associated with adverse survival because the tumors are more advanced at 
diagnosis; however, the majority of studies included only small numbers of amelanotic 
melanoma cases entered at single study sites and used a clinical, not pathologic, definition of 
amelanotic melanoma or lacked centralized pathology review.
Amelanotic melanoma has been defined differently between studies, either clinically as 
melanomas devoid of pigment on visual inspection before biopsy6-8 or lacking melanin 
pigment in melanoma cells on routine hematoxylin & eosin (H&E) stained sections.9-11 
Approximately 2-20% of melanomas have been classified as amelanotic.6-11 Amelanotic 
melanomas can be found among all histologic subtypes, including superficial spreading 
(SSM), nodular (NM), lentigo maligna (LMM), and acral lentiginous (ALM) melanoma.6,12
Of all investigations using either a clinical or histopathologic definition, we are aware of 
only three studies that included more than 100 amelanotic cases.11,13,14 Moreau et al.14 
using Surveillance, Epidemiology, and End Results (SEER) registry data, found that 
amelanotic melanoma was more advanced at diagnosis and more lethal than pigmented 
melanoma. However, misclassification of histolopathogically amelanotic and pigmented 
melanomas could occur in SEER data. SEER extracts the term ‘amelanotic’ from pathology 
reports and codes it under an ICD-O-3 morphology code, but the SEER registry allows 
documentation of only one morphology code.14,15 Thus, melanomas coded under a different 
morphology code (such as SSM, NM, LMM, or ALM) would not be coded as amelanotic. In 
addition, pathologists may not report ‘amelanotic’ on pathology reports, leading to missing 
data.
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The two other studies with more than 100 amelanotic cases conducted centralized pathology 
review of the melanomas.11,13 In a Norwegian population-based study, Larsen et al.13 found 
that overall survival of patients was significantly worse for amelanotic than pigmented 
melanoma but these results were not adjusted for other melanoma characteristics.In a Danish 
hospital-based study, Sondergaard et al.11 found that amelanotic melanoma patients did not 
have poorer melanoma-specific survival once other clinicopathological characteristics 
including Breslow thickness were taken into account; however, generalization of the 
findings from a single hospital study would be limited.
We examined histopathologically diagnosed amelanotic and pigmented melanomas in the 
international population-based Genes, Environment and Melanoma (GEM) study of patients 
with single primary melanomas (SPMs) and multiple primary melanomas (MPMs).16-19 
Expert pathologists reviewed and scored the histologic features, including pigmentation, of 
3,486 invasive primary melanomas diagnosed in 1998-2003 from 2,995 GEM study patients 
from Australia, the United States, Italy and Canada. We used a precise definition of 
histologic pigmentation; melanomas were recorded as histopathologically amelanotic if on 
light microscopic examination of H&E-stained sections no melanin granules were seen in 
the cytoplasm of the tumor cells. Our goals were to more fully characterize the relationship 
of histopathologic pigmentation to clinicopathologic features and current American Joint 
Committee on Cancer (AJCC) tumor stage20 and to compare melanoma-specific and overall 
survival between patients with histopathologically amelanotic and pigmented melanoma.
Methods
Population
The GEM study population included incident primary cutaneous melanomas notified to 
population-based cancer registries in Australia, Canada, Italy and the United 
States.16,17,21-23 Patients with SPM were diagnosed in 2000 and those with MPM were 
diagnosed with a second or higher order invasive or in situ melanoma in 1998–2003. We 
included incident melanomas (SPMs and index MPMs), and, for patients with MPM, also 
ascertained the previous (usually the first) melanoma (previous MPM) in local cancer 
registry records.In situ melanomas were eligible as index MPMs when the patient had a 
previous invasive melanoma. The institutional review board at the coordinating center 
(Memorial Sloan-Kettering Cancer Center) and each participating institution approved the 
study protocol. Physician approval was sought before contacting eligible participants. All 
study participants provided written informed consent, including for obtaining diagnostic 
slides of their melanoma(s) for centralized review.
In GEM, there were 3,578 participants with a total of 4,784 primary cutaneous melanomas. 
This analysis excluded in situ melanomas (n = 302) because the aims were to determine the 
association of histopathologic pigmentation with clinical and pathologic features of and 
survival from invasive melanomas. The analyses reported here included only primary 
invasive melanomas for which the diagnostic slides were available for review and centrally 
scored for histopathologic pigmentation, a total of 3,486 (78% of 4,482) primary invasive 
melanomas from 2,955 (82% of 3,578) GEM participants. They comprised 2,007 index 
SPMs (85% of 2,372), 716 index MPMs (79% of 904) and 763 previous MPMs (63% of 
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1,206). The 716 index MPMs and 763 previous MPMs occurred in 948 MPM patients (79% 
of 1,206), among whom 185 had pathology reviewed for only the index MPM, 232 for only 
the previous MPM and 531 for both.
Centralized Pathology Review
Patient age, sex, and melanoma body site were extracted from pathology reports and 
confirmed during patient interview; histologic subtype and Breslow thickness were also 
extracted from pathology reports. Centralized review of the melanoma H&E-stained slides 
recorded histologic subtype, Breslow thickness, pigmentation, mitoses, ulceration, tumor 
infiltrating lymphocytes, adjacent solar elastosis, and co-existing nevus. Melanomas were 
classified according to previously reported criteria.24,25 Mitoses were defined as present or 
absent.26
Melanomas were recorded as histopathologically amelanotic if on light microscopic 
examination of H&E-stained sections no melanin granules were seen in the cytoplasm of the 
tumor cells. In a test set of 19 sections scored for melanin pigmentation by the three 
dermatopathologists who reviewed the GEM melanomas, the kappa statistic for agreement 
between the pathologists was 0.48, which indicates moderate agreement.
From one study center (North Carolina), we extracted pre-biopsy impression of lesional 
(‘clinical’) pigmentation from the pathology reports. ‘Clinical’ pigmentation was recorded 
on the pathology reports for only 23% (64 of 274) of the melanomas. Melanomas described 
as ‘tan, brown, blue, grey, black, or hyperpigmented’ were grouped as ‘clinically 
pigmented’, while melanomas noted as ‘pink, red, white or amelanotic’ were grouped as 
‘clinically amelanotic’. Ninety-five percent (57 of 60) of ‘clinically pigmented’ melanomas 
were also histopathologically pigmented (as determined by centralized pathology review); 
while 80% (4 of 5) of ‘clinically amelanotic’ melanomas were histopathologically 
amelanotic (P < .0001; Fisher exact test). As ‘clinical’ pigmentation was often missing on 
the pathology reports but was associated with histopathologic pigment, we chose 
histopathologic pigmentation from centralized pathology review for all analyses. The North 
Carolina cancer registry ascertained these population-based cases, which were originally 
diagnosed by multiple providers across North Carolina. We did not have access to provider 
chart notes to abstract pre-biopsy melanoma color descriptions.
All data items were available for the T classification describing the state of the primary 
tumor in the AJCC TNM (tumor, regional nodes, distant metastasis) melanoma staging 
system; data on regional nodes and distant metastases were not available.
Melanoma treatment information was not available; however, the follow-up period at all 
study centers ended before US FDA, Health Canada, European Union and Australian 
Therapeutic Goods Administration approvals of CTLA-4, BRAF, and MEK inhibitors for 
treatment of metastatic melanoma.
Information about deaths from melanoma or other causes was obtained for all participants 
from National Death Indexes, cancer registries, and municipal records.Patient follow-up for 
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vital status finished at the end of 2007 in most centers and at the end of 2008 in British 
Columbia and Italy. See eMethods for additional follow-up information.
Statistical Analysis
The association of clinical and pathologic characteristics with amelanotic and pigmented 
melanoma was examined including all single and multiple (both index and previous) 
primary melanomas. We used marginal logistic regressions with an independent correlation 
structure implemented in generalized estimating equations (GEE) to account for the 
clustering of melanomas for MPM patients. All models included study center and lesion 
status (SPM, index MPM, previous MPM), the design variables. To identify factors that 
independently distinguished amelanotic from pigmented melanoma, a multivariable model 
was developed that included all clinicopathologic features and study design variables [study 
center and lesion status (SPM, index MPM, or previous MPM)]. Statistical significance was 
evaluated based on Wald tests. We also report results from similar models examining the 
association of amelanotic versus pigmented melanoma with AJCC tumor stage. Linear trend 
was tested using the Wald statistic when AJCC tumor stage was treated as a single ordinal 
variable.
Previous analyses of GEM data required the inclusion of an age by sex interaction term 
because of the higher population incidence of melanoma in younger women than men but 
lower incidence in women than men at older ages.17 In this report, we tested for the presence 
of such an interaction by adding an age by sex interaction term to the model. We also 
examined the relation of pigmentation to Breslow thickness and age categories stratified by 
sex using Pearson chi-squared tests.
Survival by amelanotic and pigmented melanoma was examined in all patients, including all 
SPM and MPM patients. For MPM patients with review data for both the index and a 
previous MPM, we used the pathology characteristics of the tumor with the greatest Breslow 
thickness in the analysis. When thickness was the same for both melanomas, we used the 
characteristics of the index MPM; and, if one MPM had thickness missing (n = 30), the 
pathology characteristics of the other were used. Since the parent study involved population-
based ascertainment of incident SPM and MPM, survival time was accumulated from the 
diagnosis date of the index lesion, whether SPM or MPM. The endpoint was date of death 
due to melanoma or the end of complete follow-up (censored patients). For melanoma-
specific survival, patients were censored at the time of death from any cause other than 
melanoma.
Survival curves by lesion pigmentation were constructed using the Kaplan-Meier method 
and compared using a log-rank test. Hazard ratios (HR) and 95% confidence intervals (95% 
CI) for melanoma-specific survival by pigmentation were estimated in Cox regression 
models. The time-scale used in the Cox regression models was follow-up time, adjusting for 
baseline age as a covariate.For 96 patients enrolled as SPM patients who experienced a 
subsequent melanoma during the period of participant recruitment, a time-dependent 
covariate for MPM status was included in the model at the date of diagnosis of a second 
melanoma. An initial Cox model was adjusted for age, sex, site, and study center and 
whether SPM or MPM and another model also included AJCC tumor stage. A separate fully 
Thomas et al. Page 6






















adjusted Cox model for overall survival by amelanotic compared to pigmented melanoma is 
also presented.
Tests based on Schoenfeld residuals and graphical methods using Kaplan-Meier curves in 
STATA/IC 12.1 (StataCorp LP, College Station, TX) showed no evidence that proportional 
hazards assumptions were violated for pigmentation. All significance tests were two-sided. 
SAS (SAS Institute, Cary, NC) version 9.3 was used for all analyses except for Kaplan-




Overall 275 (8%) of the melanomas were amelanotic (Table 1). We examined associations 
of the clinicopathologic characteristics with amelanotic melanoma for 3,207 SPMs and 
MPMs with complete data for all variables of interest (Table 2). Notably, the median 
thickness of amelanotic melanomas (1.60 mm) was much greater than pigmented 
melanomas (0.68 mm). We observed some differences between the sexes depending on age 
and Breslow thickness. More of the melanomas in men age >70 years were amelanotic 
(10%) compared to men 50-69 years (7%) or men <50 years (4%) (P = .007), while in 
women 8-10% of melanomas were amelanotic in each age group (P = .55) (eTable 1). 
Amelanotic melanoma was associated (P < .001) with Breslow thickness >2.00 mm in each 
sex, but a higher percentage of men had thicker amelanotic melanomas (48% >2mm) than 
women (35% >2mm) (P=.05).
Age and each of the clinicopathologic characteristics, but not sex, were associated (P < .05) 
with amelanotic melanoma when adjusted only for the design variables – study center and 
lesion status (SPM, index MPM, or previous MPM) (Table 2). When all variables were 
included in one fully adjusted model, the variables independently associated (P< .05) with 
amelanotic melanoma were female sex, nodular and unclassified or other histologic 
subtypes, increased Breslow thickness, presence of mitoses, severe solar elastosis, and lack 
of a co-existing nevus.
The odds ratio (OR) for amelanotic melanoma in women relative to men was significantly 
increased in the fully adjusted model (OR, 1.4; 95% CI, 1.0-2.0) but not in the model 
adjusted only for study design variables (OR, 1.1; 95% CI, 0.8-1.4), an effect accounted for 
by the inclusion of thickness in the fully adjusted model. Ulceration and tumor-infiltrating 
lymphocytes each became non-significant in the fully adjusted model due to addition of 
thickness to the model. The age by sex interaction term was not significant when added to 
the fully adjusted model (P for interaction=.22) and no OR in the model changed by >10%; 
thus, we did not include the interaction term in the models.
We examined in more detail the association of amelanotic melanoma with individual AJCC 
tumor stage adjusted for factors known to be associated with survival (sex, age, and 
anatomic site) along with the design variables (Table 3). Melanomas with higher AJCC 
tumor stage were more likely to be amelanotic, with Ors between 2.9 and 11.1 for tumor 
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stages between T1b and T3b and ORs of 24.6 for T4a and 29.1 for T4b relative to T1a (P for 
trend <.001).
Melanoma-Specific Survival
There were 208 melanoma deaths in 2,736 GEM patients with complete AJCC tumor stage 
information; the median follow-up time was 7.6 years. Kaplan-Meier survival curves show 
5-year melanoma-specific survival of 88% (95% CI, 84-92%) in amelanotic and 95% (95% 
CI, 94-96%) in pigmented melanoma (P<.001, log-rank test) (Figure 1). The HR for 
melanoma death was 2.0 (95% CI, 1.4-3.0; P < .001) for amelanotic relative to pigmented 
melanoma in a Cox regression model adjusted for age, sex, anatomic site, study center and 
whether SPM or MPM (Table 4). However, addition of AJCC tumor stage to the above 
model removed the association of amelanotic relative to pigmented melanoma with 
melanoma-specific survival (HR, 0.8; 95% CI, 0.5-1.2; P=.36).
In a reanalysis of SPMs alone, death from melanoma remained higher for amelanotic than 
pigmented melanoma (HR, 2.4; 95% CI, 1.5-3.8); P < .001) adjusted for age, sex anatomic 
site, and study design variables; but survival did not differ once AJCC tumor stage was also 
taken into account (HR 0.8; 95% CI, 0.5-1.2; P = .26) (not shown in tables).
Overall Survival
Hazard of death from all causes was higher for histopathologically amelanotic than 
pigmented melanoma (HR, 1.6; 95% CI, 1.2-2.1), adjusted for age, sex anatomic site, and 
study design variables (P = .001; not shown in tables); however, survival did not differ once 
AJCC tumor stage was also taken into account, (HR, 0.9, 95% CI, 0.7-1.2; P = .44) (eTable 
2).
Discussion
Female sex, nodular and unclassified or other subtypes, increased Breslow thickness, 
presence of mitoses, severe solar elastosis, and lack of a co-existing nevus were 
independently associated with histopathologically amelanotic melanoma in the international 
population-based GEM study. Amelanotic melanomas were more frequent among 
melanomas with higher AJCC stage at diagnosis. Melanoma-specific fatality was higher for 
amelanotic compared to pigmented melanoma but not once AJCC tumor stage was taken 
into account.
The 8% frequency of histopathologic amelanotic melanoma in our study is within the range 
of the 2-20% of melanomas previously reported as histopathologically 
amelanotic.7,9-11,131414 Other studies have found amelanotic melanoma to be associated 
with older age6,14 head/neck14 site and sun-damaged skin,27 as we did. However, solar 
elastosis, which we have shown is associated with cumulative site-specific ambient 
erythemal UV exposure,28 was a stronger predictor of amelanotic melanoma in GEM than 
age or site. Like us, others have reported that NMs6,13,29 were more likely to be amelanotic. 
We contribute to the literature that unclassified and histological types other than NM, SSM 
or LMM were also independently associated with amelanotic melanoma. Further, we found 
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lack of a co-existing nevus to be independently associated with amelanotic melanoma also, 
apparently, for the first time.
Other studies have variably reported predilection of amelanotic melanoma for females,6,7 
males14,30 or neither sex.31 In unadjusted analyses, we observed that younger (< 50 years) 
females were more likely than males of a similar age to have amelanotic than pigmented 
melanoma but there was little difference at older (>50 years) ages. Men generally had 
thicker melanomas. Being female increased the likelihood that a melanoma was an 
amelanotic melanoma but only after taking into account Breslow thickness and age. We 
speculate that women on the whole might self-refer for suspicious lesions that prove to be 
amelanotic melanomas more often than men do.
As we found, amelanotic melanoma has been reported as positively associated with 
increased Breslow thickness10,14,29 and presence of mitoses in other studies.13 Notably, Liu 
et al. reported rapid rate of melanoma growth, which they found correlated moderately to 
strongly with mitotic rate, to be associated with histopathologically amelanotic melanoma.32 
We report that the association of mitoses with amelanotic melanoma is independent of 
Breslow thickness and other clinicopathologic characteristics. Because mitoses are generally 
considered as a marker for tumor growth,33 our finding suggests that amelanotic melanomas 
grow faster than pigmented melanomas.
Previous studies variably found ulceration to be more frequent in14,34 or not associated 
with6 amelanotic melanoma. In GEM, ulceration and higher tumor-infiltrating lymphocyte 
(TIL) grade were each positively associated with amelanotic melanoma in GEM patients but 
not after accounting for thickness. No study that we are aware of has examined TIL grade in 
relationship to histopathologic pigmentation of melanoma; however, amelanotic melanomas 
have been reported to frequently retain pigment cell differentiation antigens.30,35,36 We 
speculate that this may render histopathologically amelanotic and pigmented melanomas 
similarly antigenic and lead to comparable lymphocytic infiltrates.
Like GEM, one other large study that included greater than 100 amelanotic melanomas and 
conducted centralized pathology review found no difference in melanoma-specific survival 
for histopathologically amelanotic versus pigmented melanoma after accounting for their 
generally more advanced tumor stage.11 It is probable that amelanotic melanomas tend to 
present at a more advanced tumor stage because they are more difficult to diagnose. A high 
rate of clinical misdiagnosis for amelanotic melanoma has been reported.6,27,37 Lack of 
melanin granules in histopathologically amelanotic melanoma could affect use of the color 
criterion in the ABCDE algorithm38 and impact early recognition. One group attempted to 
measure diagnostic delay using a clinical, not pathologic, definition of amelanotic 
melanoma. Betti et al.39 reported a greater delay in amelanotic melanoma diagnosis due 
principally to physician diagnostic delay but the same group29 subsequently reported no 
significant diagnostic delay. Additional studies could clarify the issues surrounding delays in 
diagnosis of amelanotic melanoma.
We are not aware of another international study comparing survival from amelanotic and 
pigmented melanoma, nor has another population-based study examined survival by 
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pigmentation of centrally reviewed melanomas while taking into account tumor stage. Other 
advantages of our study include its large size, collection of information about cause of death, 
objective histopathologic definition of tumor pigmentation, use of current AJCC tumor 
staging, and long observational period ending before recent US Food and Drug 
Administration approvals of new agents,2-5 which could differentially alter the natural 
course of disease. As BRAF-mutant melanoma has been reported to be associated with 
histologic pigmentation,40 future survival studies of amelanotic melanoma in relationship to 
survival could be confounded by treatments targeting the BRAF-MEK pathway.2,4,5
A study weakness is that histopathologically amelanotic and pigmented melanoma may be 
misclassified for some cases; the interobserver agreement for scoring of histopathologic 
pigmentation was moderate (kappa = 0.48). Others have also noted difficulty grading 
pigmentation,13 although we are not aware of any prior interobserver studies for 
histopathologic pigmentation. Another limitation is that we were unable to access pre-biopsy 
color descriptions of the melanomas from provider charts.
In conclusion, the poorer melanoma-specific and overall survival for histopathologically 
amelanotic compared to pigmented melanoma in GEM was entirely due to higher tumor 
stage at diagnosis of amelanotic melanomas. It is very likely that amelanotic tumors 
presented at a higher AJCC tumor stage due to delayed diagnosis. The positive association 
of mitoses with amelanotic melanoma independent of tumor thickness and other 
clinicopathologic characteristics suggests that amelanotic melanomas may grow more 
rapidly than pigmented melanomas. If this is the case, amelanotic melanomas may not only 
be more difficult to diagnose but the window of opportunity for early diagnosis might be 
smaller. Although amelanotic melanoma was associated with severe solar elastosis, it 
occurred on all body sites, supporting complete skin examinations for its detection. Studying 
a subset of cases, we found that ‘clinical’ pigmentation was associated with 
‘histopathologic’ pigmentation. Future research is needed to identify the best methods for 
diagnosis of amelanotic melanoma. Studying the biology of amelanotic melanoma could 
shed light on the possibility that it has a faster growth rate than pigmented melanoma.
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Fig 1. Kaplan-Meier Survival Curves
Kaplan-Meier melanoma-specific survival probabilities by histopathologically amelanotic 
and pigmented melanoma are shown for patients with melanoma (n = 2,736) with median 
follow-up of 7.6 years.
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Table 1
Characteristics of 3,486 Primary Invasive Cutaneous Melanomas Centrally Reviewed for 
Histopathologic Pigmentation from 2,995 Patientsa
No. (%) of Melanomas
All SPM and MPMs SPMs Index MPMs Previous MPMs
Characteristic (n=3,486) (n=2,007) (n = 716) (n =763)
Sex
 Male 2,029 (58) 1,020 (52) 496 (69) 513 (67)
 Female 1,457 (42) 987 (48) 220 (31) 250 (33)
Age at diagnosis, y
 Median (IQR) 60 (47-71) 54 (44-68) 67 (56-75) 64 (53-72)
Histopathologically amelanoticb
 No 3,211 (92) 1,823 (91) 670 (94) 718 (94)
 Yes 275 (8) 184 (9) 46 (6) 45 (6)
Abbreviations: IQR, interquartile range; SD, standard deviation; SPM, single primary melanoma; MPM, multiple primary melanoma.
a
Patients were included who had histologic pigment scored in their melanoma.
b
Melanomas were recorded as amelanotic if on light microscopic examination of H&E-stained sections no melanin granules were seen in the 
cytoplasm of the tumor cells on centralized slide review by expert dermatopathologists.
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Table 3
Relationship Between Histopathologic Pigmentation and AJCC Tumor Stage for 3,325 
Primary Invasive Melanomas From 2,845 Patientsa
No. (%) of Melanomas
Pigmented Amelanotic Amelanotic vs. Pigmented Melanoma
AJCC Tumor Stageb (n=3,058) (n=267) Adjusted OR (95% CI)c Ptrendd
 T1a 1,720 (97) 54 (3) 1 [Reference]
 T1b 412 (92) 36 (8) 2.9 (1.8-4.6)
 T2a 506 (91) 53 (9) 3.5 (2.3-5.4)
 T2b 62 (79) 16 (21) 11.1 (5.8-21.2) <.001
 T3a 168 (82) 38 (18) 9.0 (5.6-14.5)
 T3b 103 (89) 13 (11) 4.6 (2.3-9.2)
 T4a 51 (64) 29 (36) 24.6 (13.6-44.4)
 T4b 36 (56) 28 (44) 29.1 (15.5-54.9)
Abbreviations: AJCC, American Joint Committee on Cancer; OR, odds ratio; CI, confidence interval.
a
Invasive single melanomas and multiple melanomas (index and previous) with missing data for stage (n = 161) were excluded. We used marginal 
logistic regression with an independent correlation structure implemented in generalized estimating equations to account for the clustering of 
melanomas for multiple primary melanoma (MPM) patients.
b
T1a, Breslow thickness ≤1.0 mm and absence of ulceration or mitoses; T1b, Breslow thickness ≤ 1.0 mm and presence of ulceration or mitoses; 
T2a, Breslow thickness 1.01-2.0 mm without ulceration; T2b, Breslow thickness 1.01-2.0 mm with ulceration; T3a, Breslow thickness 2.01-4.0 mm 
without ulceration; T3b, Breslow thickness 2.01-4.0 mm with ulceration, T4a, Breslow thickness > 4.0 mm without ulceration; T4b, Breslow 
thickness > 4.0 mm with ulceration.
c
Adjusted for age (<50, 50-69, >70), sex, anatomic site (trunk, head/neck, upper extremities, lower extremities), study center, and lesion status 
(single primary melanoma, index MPM, or previous MPM).
d
Ptrend was calculated in the generalized estimating equation model including stage as an ordinal variable.
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